new glp-1 drugs in development A wave of weight-loss therapies aims to be better than today's GLP-1s Frontiers | Beyond GLP-1: underexplored

In the SURPASS-EARLY trial, nearly 800 adults diagnosed with type 2 diabetes within the past four years whose disease was not adequately controlled with metformin, diet and exercise were assigned to add either tirzepatide or other medications

9 kg), reduces depression scores and improves QoL dimensions such as mood and self-image, with changes correlating with the magnitude of weight loss (138)

Serious adverse events with tirzepatide are rare but include pancreatitis, gallbladder problems, and potential thyroid concerns (based on animal studies)

Andrew Dillin, quoted in this New York Times article on rapamycin, thinks not: Why take risks with unproven benefits? he told The Times

29 The mean eGFR was 61 ml/min/1.73 m

Meisha K